The first component of complement (C1) inhibitor plays a critical role in the regulation of the classical complement pathway and the contact system, and the deficiency of C1 inhibitor protein or function is associated with recurrent angioedema. In this study we evaluated the size of the C1 inhibitor antigens present in the plasmas of C1 inhibitor-deficient patients. We found that the Cl inhibitor in the plasmas existed in three forms: high molecular weight forms in complex with proteases, native MAO-kD C1 inhibitor, and a modified inactive 94-kD form. The proportion of the total C1 inhibitor in the 94-kD form was 28% in nine hereditary angioedema patients, 92% in five acquired C1 inhibitordeficiency patients, and 1.2% in five normal controls. In vitro activation of normal plasma with kaolin, but not heat-aggregated gamma-globulin generated 94-kD C1 inhibitor from 11O-kD C1 inhibitor. Neither kaolin activation nor heat-aggregated gammaglobulin activation generated 94-kD C1 inhibitor in Hageman factor-deficient plasma. These results suggest that 94-kD C1 inhibitor is generated in vitro by activation of the contact system. The in vivo mechanism of 94-kD C1 inhibitor generation in C1 inhibitor-deficient patients is not known.
Introduction
Three distinct syndromes of Cl inhibitor deficiency occur in humans and are associated with complement activation and recurrent angioedema: hereditary angioedema (HAE)' (1) and variant HAE (2) are inherited in an autosomal dominant manner; and acquired Cl inhibitor deficiency (3) (4) (5) usually occurs in conjunction with a lymphoproliferative disease or paraproteinemia. The pathogenesis of edema formation in the C inhibitordeficiency syndromes is not completely understood. Increased vascular permeability capable of causing edema formation has been ascribed to complement activation with release of a C2 kinin (6, 7) and/or contact system activation with release of bradykinin (8) (9) (10) (11) (12) . The relative degrees ofcomplement activation and contact system activation in C inhibitor-deficient patients have not been compared, primarily because of the difficulty of assessing contact system activation in plasma.
Cl inhibitor is a heavily glycosylated single-chain polypeptide with a reported molecular weight of -108 kD (13) (14) (15) (16) (17) (18) (19) . It is a multifunctional serine protease inhibitor that is normally present in high concentrations in human plasma (174-240 mg/liter). Cl inhibitor is the only known plasma inhibitor of Clr and Cls (20, 21) , the activated proteases of the first component of complement (C1). Cl inhibitor is also the major plasma inhibitor of activated Hageman factor (22) (23) (24) (25) (26) (27) , the first protease in the contact system. It is also one of the major inhibitors of plasma kallikrein (8, 23, (28) (29) (30) (31) (32) , the contact system protease that cleaves kininogen and releases bradykinin. Although Cl inhibitor can inhibit coagulation factor XIa (24) and plasmin (23), the inhibition rates for these reactions are slow, suggesting that these inhibitions are not significant in vivo (33) . Thus the primary physiologic roles of Cl inhibitor appear to be regulation of activation ofthe classical complement and contact systems. However, the functional activity of Cl inhibitor in the plasmas of Cl inhibitor-deficient patients is often even less than that predicted by its plasma concentration as determined by single radial immunodiffusion (34) . The basis of this discrepancy is not entirely clear.
When Cl inhibitor regulates activated C 1, it generates stable complexes of Cl inhibitor with Clr and Cls (35) . Cl inhibitor forms sodium dodecyl sulfate (SDS)-stable complexes with Clr, Cls, kallikrein, activated Hageman factor, and plasmin (14, 15, 20, 26) . Harpel and Cooper (15) showed that plasmin and trypsin interact in vitro with Cl inhibitor to yield smaller Cl inhibitor fragments, at least one ofwhich retained functional activity. Subsequently, other investigators have demonstrated in vitro modification or proteolytic cleavage of Cl inhibitor by Cls, kallikrein, plasmin, elastase, and other serine proteases ( 14, (36) (37) (38) (39) (40) (41) .
In this paper we show that plasma from most if not all patients with Cl inhibitor deficiencies contains a nonfunctional smaller (Mr = 94 kD) form of Cl inhibitor in addition to the normal, fully functional 110-kD and protease-complexed high molecular weight forms of C I inhibitor. The 94-kD form of C I inhibitor is generated from normal 1 I0-kD Cl inhibitor by kaolin activation of normal plasma in vitro.
Methods
Patients and plasma samples. Blood from five normal, nine HAE, two variant HAE, and five acquired C l inhibitor-deficiency donors was collected into plastic syringes and mixed with sodium citrate at a final concentration of 0.38% (wt/vol). Unless it was to be activated in vitro, the blood was treated with a cocktail of protease inhibitors as follows (final concentrations): aprotinin 333 IU/ml, benzamidine 0.1 mg/ml, 1,10 phenanthroline 0.01 mM, and phenylmethylsulfonyl fluoride 1 mM. Plasma was obtained by centrifugation and was immediately aliquoted and stored at -70°C. All processing was performed in plastic tubes. The plasma was thawed immediately before analysis. Prekallikrein-deficient plasma was a gift from Dr. Charles Cochrane (La Jolla, CA). Hageman factor-deficient plasma was generously donated by Mrs. Gunda Hiatt. The acquired Cl inhibitor-deficiency patients had the following associated disorders: chronic lymphocytic leukemia (one patient), paraproteinemia (three patients), and undefined (one patient).
Antibodies. Biotinylated horse anti-mouse IgG was purchased from Vector Laboratories (Burlingame, CA). Goat anti-mouse kappa chain was purchased from Southern Biotechnology Associates (Birmingham, AL). Goat anti-human prekallikrein that recognizes both prekallikrein and kallikrein was a gift from Dr. Charles Cochrane. Anti-human Cl inhibitor and anti-human Cls antisera were prepared by immunizing goats with purified proteins. The antisera were monospecific by Ouchterlony and immunoelectrophoresis analysis. The production ofthe murine monoclonal anti-Cl inhibitor antibody has been previously described (42) .
In vitro activation ofplasma. For some experiments plasma was activated in vitro with either kaolin (aluminum silicate) or heat aggregated gamma-globulin (20 mg/ml in Ca" containing veronal buffer heated at 560C for 1 h). Kaolin was added to citrated plasma (without inhibitors) at a final concentration of I mg kaolin/ml plasma and incubated at 370C for 60 min with frequent shaking. Equal volumes of citrated plasma (without inhibitors) and heat-aggregated gamma-globulin were mixed and incubated at 370C for 60 min with frequent shaking.
Immune adsorption. IgG fractions of polyclonal goat antisera to Cls, Cl inhibitor, and prekallikrein were conjugated to cyanogen bromideactivated Sepharose 4B (Pharmacia Fine Chemicals, Uppsala, Sweden) at 5 mg of IgG/ml swollen gel. 80% or more of the IgG was coupled in each case. For immune adsorption 40 M1 of a 1:1 suspension of the conjugated Sepharose beads in phosphate-buffered saline (PBS) containing 0.05% Tween 20 (PBS-Tween) was added to 15 Al of plasma (with inhibitors), and incubated at room temperature for 1 h with frequent gentle mixing. The Sepharose beads were then washed three times with PBSTween to remove the nonadsorbed plasma constituents, and the Sepharose beads were resuspended in 80 M1 of sample buffer (0.0625 M Tris, pH 6.8, 3% SDS, 10% glycerol, and bromphenol blue). Incubation of normal plasma with anti-Cl inhibitor-conjugated Sepharose depleted all the Cl inhibitor from the plasma as determined by rocket immunoelectrophoresis (see below). The anti-prekallikrein-conjugated Sepharose immune adsorbed both prekallikrein and kallikrein, and the anti-Cls conjugated Sepharose immune adsorbed both Cls and Cls. The anti-Cls conjugated sepharose also adsorbed Clr in complex with Cls.
Immunoblottingfor Cl inhibitor. After immune adsorption, the proteins on the washed Sepharose beads were released into the sample buffer by incubation for 5 min in a boiling water bath. The Sepharose beads were pelleted, and the protein containing supernatants applied to 7.5% polyacrylamide slab gels and electrophoresed according to the method of Laemmli (43 (Fig. 2, lane 7) . The identity of these bands is not known, however, the 1 50-kD C l inhibitor band was immune adsorbed by anti-prekallikreinconjugated Sepharose beads (lane 9). Because the HAE patients had a significantly higher mean percentage of their Cl inhibitor in the high molecular weight complexed form, the identity ofthe 198-kD band was determined in five HAE patients. Fig. 4 4% after incubation with CIs. By contrast, the same plasma samples were incubated with kaolin to activate the contact system, and the mean percentage of 94-kD Cl inhibitor increased to 30%. When normal plasma was activated with heat-aggregated gamma-globulin or incubated with Cls and then kaolin activated, the percentage of 94-kD Cl inhibitor generated was approximately one halfofthat generated by kaolin activation alone.
Because kaolin activation of plasma is not specific for the contact system, the roles ofthe components ofthe contact system in the generation of 94-kD Cl inhibitor were evaluated directly by kaolin activation of plasmas deficient in Hageman factor, prekallikrein, or high molecular weight kininogen. Fig. 5 (46) , and the absence of plasminogen confirmed by double immunodiffusion assay using rabbit anti-human plasminogen (Calbiochem Behring Corp.). Kaolin activation of the plasminogen-depleted plasma increased the percentage of 94-kD Cl inhibitor from <1% to 15% (Fig. 6, lanes 3 and 4) . Kaolin activation of the non-depleted plasma increased the percentage of 94-kD Cl inhibitor to 20% (lanes 1 and 2) . The ability ofplasmin to generate 94-kD Cl inhibitor was determined by the addition ofstreptokinase to plasma. In order to avoid secondary activation ofthe contact system, Hageman factor-deficient plasma was used. Plasmin activity was monitored by the cleavage of '251-fibrin (Table IV) (47) . Streptokinase treatment of Hageman factordeficient plasma generated <1% 94-kD Cl inhibitor (lane 5). When streptokinase was added to normal plasma, 7% 94-kD Cl inhibitor was generated (lane 6) . The addition of streptokinase to a mixture of purified Cl inhibitor and purified plasminogen yielded a 182-kD high molecular weight complex containing Cl inhibitor as well as an 84-kD form of Cl inhibitor (lane 8). These 182-and 84-kD Cl inhibitor bands are clearly distinguishable from the 198-and 21 3-kD complexes and 94-kD form of Cl inhibitor. 94-kD Cl inhibitor is functionally inactive. The functional activity of 94-kD Cl inhibitor was assessed by its ability to form stable complexes with CIr, Cls, and kallikrein. Ml of acquired Cl inhibitor-deficient plasma (lane 2). The immune adsorbed proteins were separated in 7.5% SDS-PAGE, electrotransferred to nitrocellulose, and immunoblotted using monoclonal anti-CI inhibitor and an enzyme immunoassay.
inhibitor in acquired Cl inhibitor-deficiency plasma to complex with purified Cls was determined directly. Purified active Cls (53) was immune adsorbed to anti-Cls-conjugated Sepharose beads, and the beads were incubated with either normal or acquired Cl inhibitor deficiency plasma as sources ofC1 inhibitor.
The, adsorbed proteins were separated, transferred and immunoblotted for Cl inhibitor (Fig. 7 B) The structural basis of the generation of 94-kD Cl inhibitor from 1 10-kD Cl inhibitor has not been elucidated. One possibility involves limited proteolytic cleavage of Cl inhibitor by the protease. There is significant precedent for this mechanism (described below). Because the antibody used to detect Cl inhibitor in our experiments was monoclonal and reacted with the native molecule and the 94-kD form, we would not expect it to also recognize an epitope on a smaller fragment. Therefore, it is possible that such a fragment was generated but not detected. The other possibility is that the Cl inhibitor was conformationally altered by its interaction with protease. Reduction of Cl inhibitor has been shown to cause it to migrate faster on SDSpolyacrylamide gels (14, 37) and has been associated with loss of ordered secondary structures as assessed by circular-dichroism spectra (38) . Studies are currently in progress to determine which mechanism is operative.
Cl inhibitor shares many structural and functional similarities with the other serine protease-specific plasma inhibitors, and is said to belong to the alpha,-proteinase inhibitor class (33) . The inhibitors of this class are thought to form an acyl-intermediate between a carbonyl carbon ofthe inhibitor at its reactive site and the gamma oxygen ofthe protease serine (54) (39) reported that kallikrein generated a 95-kD form of C1 inhibitor from native 105-kD Cl inhibitor in vitro. They described a monoclonal antibody that recognized a neoantigen that is expressed by the kallikrein-Cl inhibitor complex and the 95-kD Cl inhibitor but not the native 105-kD Cl inhibitor.
Other investigators have demonstrated that the in vitro formation of Cls-Cl inhibitor complexes generates a small (-5 kD) fragment of Cl inhibitor (37, 38, 40) . This fragment has been shown to result from the cleavage of a single argininethreonine peptide bond at the carboxy end of the C1 inhibitor molecule (38, 40) . However, the Cls-modified Cl inhibitor complex remained stable and migrated as a single high molecular weight band on SDS-polyacrylamide gels in two of these three reports (38, 40) . One group has reported that the in vitro formation ofCls-Cl inhibitor complexes in the presence of heparin (1:1 molar ratio with Cl inhibitor) led to the generation of a modified 95-kD Cl inhibitor on SDS-polyacrylamide gels (37) . However the heparin concentration employed in these experiments was at least 10-fold higher that those achieved even during full anticoagulation (64) . In addition, the Cls-Cl inhibitor complexes were formed in a tris-HCl buffer, pH 8 .0. The pKa of Tris is 8.1, and at this pH Tris has significant nucleophilic reactivity towards carbonyl carbons (65) . Cls-Cl inhibitor complexes have previously been shown to be susceptible to dissociation by nucleophilic attack (49) . We, as well as other investigators (15, 20, 41, 49) , found that neither complement activation with heataggregated gamma-globulin nor direct addition of Cls led to significant generation of 94-kD Cl inhibitor in plasma. Taken together with our other results involving in vitro contact system activation and the use of contact system protease-deficient plasmas, this suggests that contact system activation may be a major pathway of 94-kD Cl inhibitor generation in vivo.
Because the contact system and other proteases may be poorly regulated in Cl inhibitor-deficiency states, it was necessary to exclude in vitro protease activation as the genesis of 94-kD Cl inhibitor generation in our patient samples. We have prepared plasma from Cl inhibitor-deficient patients from blood drawn simultaneously by our usual technique as well as through a largebore plastic catheter directly into a syringe containing the protease inhibitors. The Cl inhibitor in each of the plasmas was then immune adsorbed and immunoblotted. No differences in Cl inhibitor distribution between the two collection techniques was observed. These results indicate that the 94-kD Cl inhibitor was generated in vivo. There were consistent differences in the distribution of 94-and lIO-kD Cl inhibitor among the Cl inhibitor-deficient groups. The patients with acquired Cl inhibitor deficiency all had very high percentages of their Cl inhibitor in the 94-kD form whereas the common HAE group had elevated but lower percentages of 94-kD Cl inhibitor. The variant HAE group exhibited a lower percentage of 94-kD Cl inhibitor presumably because their dysfunctional Cl inhibitor was unable to bind the relevant protease(s). The total Cl inhibitor concentration did not correlate with the amount of 94-kD Cl inhibitor present in plasma. We suggest that the amount of94-kD Cl inhibitor present in plasma is dependent on the ability of the Cl inhibitor to bind to the relevant protease(s), and reflects the degree ofcontact system or other protease activation that has occurred.
This study shows that normal Cl inhibitor undergoes modification during the in vitro kaolin activation of plasma to yield a nonfunctional small Cl inhibitor of 94 kD. The 94-kD Cl inhibitor has been identified and quantified in plasma from normal individuals and Cl inhibitor-deficient patients for the first time. This is also the first in vivo corroboration that inactive modified serine protease inhibitors are formed by the interaction of protease with inhibitor. These studies suggest that contact system activation may be an important mechanism in the pathophysiology ofangioedema as first proposed by Landerman et al. (8) . This suggestion is consistent with the previous finding of large amounts of active kallikrein in blister fluids of HAE patients (12) . Cls may also be an important mediator of angioedema; however, the results presented in this report do not directly address this possibility. Finally, we suggest that quantitation of 94-kD Cl inhibitor may provide a useful probe for evaluating contact system activation in other inflammatory disorders.
